{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:05:53Z","timestamp":1793815553060,"version":"4.6.1"},"reference-count":48,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T00:00:00Z","timestamp":1646870400000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Science and Technology Planning Project of Guangdong Province, China","award":["2017B020227003"],"award-info":[{"award-number":["2017B020227003"]}]},{"name":"The Guangdong Natural Science Foundation, Guangdong Province, China","award":["2018A030310237"],"award-info":[{"award-number":["2018A030310237"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81773110, 81803079, 81902638, 81901764, 81872118"],"award-info":[{"award-number":["81773110, 81803079, 81902638, 81901764, 81872118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Planning Project of Guangzhou, Guangdong Province, China","award":["201704020215"],"award-info":[{"award-number":["201704020215"]}]},{"name":"the National Key R&D Program of China","award":["2018YFC1313400"],"award-info":[{"award-number":["2018YFC1313400"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Platinum resistance is a major challenge in the clinical treatment of advanced ovarian cancer (OC). Accumulating evidence shows that the tumor-promotive M2 macrophage is linked to the limiting chemotherapy efficacy of multiple malignancies including OC. Circular RNAs (circRNAs) are a novel class of non-coding RNAs which function as the critical regulator in biological process of cancer. However, their impact on macrophage polarization and chemoresistance of OC remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Platinum-resistant circRNAs were screened using circRNA deep sequencing and validated using in situ hybridization in OC tissues with or without platinum resistance. The role of circITGB6 in inducing cisplatin (CDDP) resistance was evaluated by clone formation, immunofluorescence and annexin V assays in vitro, and by intraperitoneal tumor model in vivo. The mechanism underlying circITGB6-mediated tumor-associated macrophage (TAM) polarization into M2 phenotype was investigated using RNA pull-down, luciferase reporter, electrophoretic mobility shift, RNA binding protein immunoprecipitation (RIP), ELISA and immunofluorescence assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified that a novel circRNA, circITGB6, robustly elevated in tumor tissues and serums from patients with OC with platinum resistance, was correlated with poor prognosis. circITGB6 overexpression promoted an M2 macrophage-dependent CDDP resistance in both vivo and vitro. Mechanistic research determined that circITGB6 directly interacted with IGF2BP2 and FGF9 mRNA to form a circITGB6\/IGF2BP2\/FGF9 RNA\u2013protein ternary complex in the cytoplasm, thereby stabilizing FGF9 mRNA and inducing polarization of TAMs toward M2 phenotype. Importantly, blocking M2 macrophage polarization with an antisense oligonucleotide targeting circITGB6 markedly reversed the circITGB6-induced CDDP resistance of OC in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reveals a novel mechanism for platinum resistance in OC and demonstrates that circITGB6 may serve as a potential prognostic marker and a therapeutic target for patients with OC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-004029","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T11:37:10Z","timestamp":1646998630000},"page":"e004029","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":150,"title":["CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype"],"prefix":"10.1136","volume":"10","author":[{"given":"Han","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuzhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhu","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengze","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaopin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-3967","authenticated-orcid":false,"given":"Jian-Chuan","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,11]]},"reference":[{"key":"2023071206453647000_10.3.e004029.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"2023071206453647000_10.3.e004029.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2023071206453647000_10.3.e004029.3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","article-title":"Hopes and failures in front-line ovarian cancer therapy","volume":"143","author":"Tsibulak","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2023071206453647000_10.3.e004029.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2014.02.038"},{"key":"2023071206453647000_10.3.e004029.5","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17648"},{"key":"2023071206453647000_10.3.e004029.6","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.7150\/jca.20314","article-title":"Immune cell population in ovarian tumor microenvironment","volume":"8","author":"Cai","year":"2017","journal-title":"J Cancer"},{"key":"2023071206453647000_10.3.e004029.7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00024"},{"key":"2023071206453647000_10.3.e004029.8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.trecan.2016.12.005","article-title":"Tumor-Host cell interactions in ovarian cancer: pathways to therapy failure","volume":"3","author":"Pogge von Strandmann","year":"2017","journal-title":"Trends Cancer"},{"key":"2023071206453647000_10.3.e004029.9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-0788"},{"key":"2023071206453647000_10.3.e004029.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.01.006"},{"key":"2023071206453647000_10.3.e004029.11","doi-asserted-by":"publisher","DOI":"10.1038\/nri3088"},{"key":"2023071206453647000_10.3.e004029.12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28335"},{"key":"2023071206453647000_10.3.e004029.13","doi-asserted-by":"publisher","DOI":"10.7150\/thno.52442"},{"key":"2023071206453647000_10.3.e004029.14","doi-asserted-by":"publisher","DOI":"10.1080\/15476286.2015.1020271"},{"key":"2023071206453647000_10.3.e004029.15","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2015.82"},{"key":"2023071206453647000_10.3.e004029.16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12429"},{"key":"2023071206453647000_10.3.e004029.17","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0643-z"},{"key":"2023071206453647000_10.3.e004029.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-016-0943-0"},{"key":"2023071206453647000_10.3.e004029.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.03.020"},{"key":"2023071206453647000_10.3.e004029.20","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1002-6","article-title":"Circular RNAs in cancer: emerging functions in hallmarks, stemness, resistance and roles as potential biomarkers","volume":"18","author":"Su","year":"2019","journal-title":"Mol Cancer"},{"key":"2023071206453647000_10.3.e004029.21","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1125-9"},{"key":"2023071206453647000_10.3.e004029.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"2023071206453647000_10.3.e004029.23"},{"key":"2023071206453647000_10.3.e004029.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20140-0"},{"key":"2023071206453647000_10.3.e004029.25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-1934"},{"key":"2023071206453647000_10.3.e004029.26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3599"},{"key":"2023071206453647000_10.3.e004029.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2010.03.009"},{"key":"2023071206453647000_10.3.e004029.28","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkt1248"},{"key":"2023071206453647000_10.3.e004029.29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3144"},{"key":"2023071206453647000_10.3.e004029.30","article-title":"New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment","volume":"20","author":"Chen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023071206453647000_10.3.e004029.31","first-page":"127","article-title":"Overview of tumor cell chemoresistance mechanisms","volume":"111","author":"Gatti","year":"2005","journal-title":"Methods Mol Med"},{"key":"2023071206453647000_10.3.e004029.32","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26289"},{"key":"2023071206453647000_10.3.e004029.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2012.01.006"},{"key":"2023071206453647000_10.3.e004029.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-3694"},{"key":"2023071206453647000_10.3.e004029.35","doi-asserted-by":"publisher","DOI":"10.1172\/jci33093"},{"key":"2023071206453647000_10.3.e004029.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1353-3","article-title":"Fgf9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells","volume":"15","author":"Sun","year":"2015","journal-title":"BMC Cancer"},{"key":"2023071206453647000_10.3.e004029.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120739","article-title":"Fibroblast growth factor-9 enhances M2 macrophage differentiation and attenuates adverse cardiac remodeling in the infarcted diabetic heart","volume":"10","author":"Singla","year":"2015","journal-title":"PLoS One"},{"key":"2023071206453647000_10.3.e004029.38","doi-asserted-by":"crossref","first-page":"25845","DOI":"10.18632\/aging.202147","article-title":"The long noncoding RNA LINC01140\/miR-140-5p\/FGF9 axis modulates bladder cancer cell aggressiveness and macrophage M2 polarization","volume":"12","author":"Wu","year":"2020","journal-title":"Aging"},{"key":"2023071206453647000_10.3.e004029.39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00137","article-title":"Tumor-Associated macrophages contribute to tumor progression in ovarian cancer","volume":"4","author":"Colvin","year":"2014","journal-title":"Front Oncol"},{"key":"2023071206453647000_10.3.e004029.40","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8274.CD-10-0028"},{"key":"2023071206453647000_10.3.e004029.41","doi-asserted-by":"publisher","DOI":"10.1101\/gad.180331.111"},{"key":"2023071206453647000_10.3.e004029.42","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106645108"},{"key":"2023071206453647000_10.3.e004029.43","doi-asserted-by":"publisher","DOI":"10.1084\/jem.193.6.727"},{"key":"2023071206453647000_10.3.e004029.44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-379214"},{"key":"2023071206453647000_10.3.e004029.45","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0257-y"},{"key":"2023071206453647000_10.3.e004029.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.05.016"},{"key":"2023071206453647000_10.3.e004029.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502000102"},{"key":"2023071206453647000_10.3.e004029.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.10.005"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-004029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T09:48:12Z","timestamp":1689155292000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-004029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,11]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/jitc-2021-004029"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-004029","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}